AGL vs ENTA
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
The Advanced Deterministic Scorecard reveals a weak financial health profile with a Piotroski F-Score of 4/9, indicating borderline stability, and a missing Altman Z-Score prevents a full distress risk assessment. Profitability metrics are deeply negative, including a -5.24% profit margin, -8.86% operating margin, and a disastrous -73.31% ROE, signaling severe capital inefficiency. Despite a low Price/Sales ratio of 0.07 and a current price of $0.99, the company is unprofitable with declining revenue and negative earnings momentum, while the market has priced in extreme pessimism, as seen in a 5Y return of -96.8%. Analysts unanimously recommend a 'hold' with a target price equal to the current price, suggesting no near-term upside expectation.
ENTA shows bearish fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Concerns include weak profitability or high valuation.
Compare Another Pair
Related Comparisons
AGL vs ENTA: Head-to-Head Comparison
This page compares agilon health, inc. (AGL) and Enanta Pharmaceuticals, Inc. (ENTA) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.